title: [Interferon status of patients with non-specific ulcerous colitis and its correction with interferon inducers].
abstract: OBJECTIVE
  To examine validity of using interferon inductors (amixin and cycloferon) in combined treatment of patients with non-specific ulcerous colitis (NUC).
  
  
  METHODS
  113 NUC patients received basic antiinflammatory therapy (glucocorticoids and preparations of 5-aminosalycylic acid). Patients of groups 1 and 2 received interferon inductors (amixin and cycloferon in tables), respectively. Patients of groups 1a and 2a received placebo. All the patients were examined clinically with evaluation of interferon status and cellular immunity before and after the treatment. Colon mucosa biopsies obtained endoscopically were studied histologically.
  
  
  RESULTS
  Alpha- and gamma-interferon production by leukocytes was substantially suppressed in all the examinees against normal levels of serum and spontaneous interferon. The interferon inductors stimulated relief of clinical symptoms and eliminated endoscopic signs of the disease. Amixin and cycloferon normalized interferon status in 36.3 and 33.3% of the treated patients, respectively. No response was registered in 9.1 and 8.4%, respectively. Improvement was seen in 54.6 and 58.3%, respectively.
  
  
  CONCLUSIONS
  Cycloferon and amixin, interferon inductors, are effective in the treatment of NUC.
authors.forename: I V
authors.initials: IV
authors.lastname: Maev
authors.forename: S S
authors.initials: SS
authors.lastname: Grigorian
authors.forename: M G
authors.initials: MG
authors.lastname: Gadzhieva
authors.forename: N I
authors.initials: NI
authors.lastname: Ovchinnikova
authors.forename: T P
authors.initials: TP
authors.lastname: Ospel'nikova
authors.forename: A N
authors.initials: AN
authors.lastname: Kaziulin
mesh_terms: D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007369:Interferon Inducers / Q000009:adverse effects / Q000627:therapeutic use*; D007372:Interferons / Q000097:blood*; D008297:Male; D010919:Placebos; D013994:Tilorone / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000166:Acridines; D000893:Anti-Inflammatory Agents; D007369:Interferon Inducers; D010919:Placebos; D007372:Interferons; D013994:Tilorone; C026430:10-carboxymethyl-9-acridanone